

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

2108.0060000/MAC/DJN

Applicant/Patent Owner: Jingyu LIANG et al.

Application No./Patent No.: 10/531,049 Filed/Issue Date: U.S. Nat'l Ph of PCT/CN2002/000728; I.A. filed 17 Oct 2002

Entitled: A Natural Compound for Prevention and Treatment of Diabetes, Process for Preparing the Same, and Pharmaceutical Use Thereof

Jingyu LIANG

a individual

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☐ the assignee of the entire right, title, and interest; or
2. ☒ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is 50 %

in the patent application/patent identified above by virtue of either:

A ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Jingyu Liang
Signature

Jingyu LIANG

Printed or Typed Name

Professor
Title

12.16/05
Date

+86(25)85391289

Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Declaration for Patent Application

Docket Number: 2108.0060000/MAC/DJN

As a below named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter that is claimed and for which a patent is sought on the invention entitled **A Natural Compound for Prevention and Treatment of Diabetes, Process for Preparing the Same, and Pharmaceutical Use Thereof**, the specification of which is attached hereto unless the following box is checked:

☒ was filed on October 17, 2002;
as United States Application Number or PCT International Application Number
PCT/CN2002/000728; and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or (f) or § 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or § 365(a) of any PCT international application, which designated at least one country other than the United States of America, listed below, and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Applications(s):

			Priority Claimed	
			<input type="checkbox"/>	<input type="checkbox"/>
			Yes	No
_____ (Application No.)	_____ (Country)	_____ (Day/Month/Year Filed)		
_____ (Application No.)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>	<input type="checkbox"/>
			Yes	No

Send Correspondence to: Customer No. 26111
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934

Direct Telephone Calls to: (202) 371-2600

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first Inventor:	Jingyu LIANG
Signature of first Inventor:	<i>Jingyu Liang</i> Date: <i>12.16/05</i>
Residence:	Jiangsu, China <i>CN</i>
Citizenship:	China
Mailing Address:	Baiziting 28-8-706, Nanjing Jiangsu, CHINA 210009

Full name of second Inventor:	Feihua WU
Signature of second Inventor:	<i>Feihua Wu</i> Date: <i>12-16-05</i>
Residence:	Nanjing, China <i>CN</i>
Citizenship:	China
Mailing Address:	Dept. of Pharmacology, China Pharmaceutical University Nanjing, CHINA 210009

Full name of third Inventor:	Guanhu BAO
Signature of third Inventor:	<i>Guan hu Bao</i> Date: <i>2005.12.16</i>
Residence:	Nanjing, China <i>CN</i>
Citizenship:	China
Mailing Address:	Mail Box 224, China Pharmaceutical University Nanjing, CHINA 210009

Full name of fourth Inventor:	Qilei CHENG
Signature of fourth Inventor:	<i>Cai lei Cheng</i> Date: <i>12-16-2005</i>
Residence:	<u>Nanjing, China</u> <i>CN</i>
Citizenship:	China
Mailing Address:	Department of Phytochemistry, China Pharmaceutical University Nanjing, CHINA 210009

447113_1.DOC